The Next Big Healthcare Stock?The chart for VERV shows a prolonged downtrend since mid-2021, with multiple resistance trendlines capping price action. However, the stock is now testing a potential breakout above these trendlines and the 50-week EMA (green line), which has acted as dynamic resistance. The RSI is rising above 60, signaling increasing bullish momentum, and the latest weekly candle, up 11.28%, suggests growing buying interest. If VERV successfully holds above this breakout zone, it could push toward the $10-$15 resistance range, confirming a trend shift. However, failure to sustain above the 50EMA could result in another rejection, reinforcing the downtrend. Volume is picking up, adding weight to the bullish case, but confirmation above key levels remains crucial for a sustained move higher.
Disclaimer:
This analysis is for educational purposes only and should not be considered financial advice. Trading and investing involve risk, and independent research or consultation with a professional is recommended before making any financial decisions.
Heathcare
HCA Healthcare | HCA | Long at $299.00NYSE:HCA Healthcare: P/E of 13x, earnings are forecast to grow 6.01% per year; earnings have grown 10.6% per year over the past 5 years, and trading at good value compared to peers and industry.
From a technical analysis perspective, it dipped to my selected historical simple moving average area and may represent a buying opportunity to fill the daily price gap up to $394.00. Thus, NYSE:HCA is in a personal buy zone at $299.00.
Target #1 = $324.00
Target #2 = $362.00
Target #3 = $394.00
Humana Breaking Below Support, Targeting Drop to $215.17Humana has broken the BAMM trigger line of a Harmonic Crab pattern and is now breaking below the $387-$375 support zone.
Harmonically, we would expect to see an accelerated move down to the 1.618 PCZ aligning with the $215 price level and it could even go as low as the HOP at $152. For the time being, I will be getting very wide Bear Call Spreads with the intent on at least capturing the move down to $300.